SELLAS Life Sciences Group, Inc. Overview
Pro stress-test →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on the development of therapeutics for a range of cancer indications. The company's primary product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1) antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. The company is approaching critical Phase 3 trial readouts for its lead AML programs.
Strategic Profile
Pro stress-test →SELLAS is advancing GPS in a Phase 3 REGAL trial evaluating it as a potential maintenance therapy in patients with acute myeloid leukemia (AML) after second complete remission, with 72 events reported as of late December 2025 (80 required for final analysis). The company has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with PD-1 blocker pembrolizumab in a Phase 1/2 clinical trial. SLS009 is progressing toward a U.S. enrollment launch in Q1 2026 in newly diagnosed high-risk AML, with European expansion planned for Q2 2026.
Competitive Landscape
Pro stress-test →SELLAS competes in the oncology/hematology therapeutic space with its WT1 immunotherapy (GPS) and CDK9 inhibitor (SLS009) programs. Primary competitors include larger pharma and biotech companies developing similar AML therapies and immuno-oncology platforms. SELLAS differentiates through its dual complementary AML-focused pipeline and Merck partnership validation.
Industry Context
SELLAS Life Sciences Group, Inc. operates in Biopharmaceutical - Oncology (Clinical Stage).
Key facts
Headquarters: New York, United States